Bocodepsin Drug Asset Due Diligence Report 2026

This Bocodepsin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Bocodepsin can convert its Small molecule drug profile and HDACs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Bocodepsin (query alias: Bocodepsin)
Modality / target	Small molecule drug; HDACs; HDAC inhibitors, Epigenetic drug
Highest global status	Phase 2
Originator	OnKure, Inc.
Active developers	OnKure, Inc.

The MCP disease footprint includes NRAS Mutant Melanoma, Advanced Malignant Solid Neoplasm. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05340621	Phase 1/2	Completed	36	Primary endpoint not disclosed in English source
NCT03931681	Phase 1	Completed	34	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Outcomes with targeted therapy for NRAS-mutated melanoma: A systematic review and meta-analysis.

Not Applicable; n=527; evaluation: Negative. Reported fields: ORR = 14 % ( 4 - 30); ORR = 5 %

Nautilus, a phase 1b/2 trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM).

Phase 1/2; n=36; evaluation: Positive. Reported fields: ORR = 30 %

Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results.

Phase 1; n=26; evaluation: Positive. Reported fields: RP2D(and MTD) = 450 mg daily for intermittent dosing and 200 mg daily for continuous dosing

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Bocodepsin addresses NRAS Mutant Melanoma, Advanced Malignant Solid Neoplasm. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-09-21	OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Novel biomarkers for antitumor therapies and PRDX6 as a therapeutic cancer target”. The milestone feed surfaced a patent-application signal described as “HDAC inhibitor OKI-179 for the treatment of cancers resulting from a MAPK pathway mutation”. The milestone feed surfaced a patent-application signal described as “HDAC inhibitor OKI-179 in combination with binimetinib for the treatment of cancer”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO